What’s New

Why Impact & Cost of Chronic Migraine Comorbidities Justify “Whole-Person” Care

Chronic migraine is seldom a lone condition, explains a new white paper from the Headache & Migraine Policy Forum.  And when chronic migraine patients suffer

Read More

Trials Data Strengthens Patients’ Demands for Breakthrough Cholesterol Meds

New data on PCSK9 inhibitors is in – and it may bolster patients’ demands for the breakthrough cholesterol drugs in the face of health plan

Read More

Rising Cancer Survivorship Brings New Policy Challenges

More patients are living longer with cancer – and that’s good news.  But some face policies, health care providers and workplaces that are unprepared to

Read More

Medical Groups Propose 21 Principles for Prior Authorization Reform

The American Medical Association and 16 patient, physician, hospital and pharmacy groups have issued a resounding message to health plans: it’s time to reform prior

Read More

Government Nutrition Advice Gives Mixed Message to Pregnant Women

Eating fish offers pregnant women nutritional benefits for both themselves and their developing babies.  But, looking at newly published advice from the Food and Drug

Read More

The Obama Administration’s Final Say on Opioids

This month’s change in presidential administrations prompted some final words – and policy – from federal agencies on the subject of opioids. First, the Centers

Read More

Patient Safety Questions Linger after FDA Issues Interchangeability Guidance

New guidance from the Food and Drug Administration directs companies on how to demonstrate a biosimilar’s interchangeability with its reference product.  The draft outlines the

Read More

Who Pays the Price for Health Plans’ Soaring Profits?

UnitedHealth Group announced higher than expected earnings this week, celebrating an 18 percent year-over-year increase to $185 billion in 2106 revenue.  But not everyone’s cheering.

Read More

FDA Settles on Random Suffix Approach for Naming Biologics & Biosimilars

The names of biologic and biosimilar medicines will include randomly generated four-letter suffixes, the Food and Drug Administration announced Thursday. The agency’s final guidance followed

Read More

***PRESS RELEASE*** Physician Group Issues Statement on FDA’s Biologic Product Naming Guidance

WASHINGTON – The Alliance for Patient Access (AfPA) issued the following statement today on the FDA’s final guidance on the nonproprietary naming of biological products. STATEMENT FROM BRIAN

Read More
Back to Top